Sponsor: Stride

Stride helps people understand and improve their wellbeing and longevity through personalised DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science.

Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount.

Affiliate link: https://www.getstride.com/unlocked/

____________________

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick explore cutting-edge developments in longevity, from hibernating animals inspiring obesity treatments to AI-driven industry insights and the world’s first Parkinson’s test kit.

• FaunaBio identified a metabolic target from hibernating mammals that could preserve muscle during weight loss. The California-based company said the achievement triggers an undisclosed milestone payment as part of a multi-year agreement signed with Lilly in 2023, which could be worth up to $494 million. This will advance this first-in-class approach, signaling serious pharma conviction in extreme-animal-inspired drug discovery.
• Longevity.Technology developed DLT (Decoding Longevity Trends), a three-stage AI system to gather, fact-check, and synthesize complex longevity data. DLT tracks over 700 longevity and age-related disease biotechs in paid-beta; the broader datasets (800+ wider ecosystem companies and 300+ longevity clinics) will be released in 2H26.
• The MODAG's PD Detect kit measures alpha-synuclein aggregates in cerebrospinal fluid with 97.8% sensitivity and 100% specificity, moving Parkinson’s diagnosis from observation to evidence. Early detection can help enroll patients at stages where disease-modifying drugs have the best chance of success.
• The Senotherapeutics Biomarker Consortium (SBC) aims to standardize cellular senescence measurement in humans to support regulators, clinicians, and drug development. Framed as a precompetitive collaboration, it brings together academia, industry and regulators to do something less glamorous than drug discovery, but arguably more necessary – to agree on how senescence should be measured, validated and ultimately trusted in the clinic.
• The experimental pill Enlicitide lowered LDL cholesterol by 57% in a phase three trial of 2,909 patients with cardiovascular risk. Daily oral dosing could finally improve compliance compared with injectable PCSK9 inhibitors, potentially reducing cardiovascular events at a population level.
• Cardiovascular disease and cancer (particularly colon cancer) and “external causes” remain top mortality risks. These conditions are leading causes of death for Gen X and Millennials, highlighting the urgent need for early detection and preventive health strategies.

____________________

News & References:

• Fauna Bio hits key milestone in Lilly obesity drug collab → https://longevity.technology/news/fauna-bio-hits-key-milestone-in-lilly-obesity-drug-collab/
• Longevity.Technology has quietly become an AI company → https://longevity.technology/news/longevity-technology-has-quietly-become-an-ai-company/
• MODAG brings world’s first Parkinson’s test to market → https://longevity.technology/news/modag-brings-worlds-first-parkinsons-test-to-market/
• Senescence consortium targets biomarker gap → https://longevity.technology/news/senescence-consortium-targets-biomarker-gap/
• Experimental pill cuts ‘bad cholesterol’ by up to 60% → https://longevity.technology/news/experimental-pill-cuts-bad-cholesterol-by-up-to-60/
• Longevity wake-up call for younger generations → https://longevity.technology/news/longevity-wake-up-call-for-younger-generations/

____________________

Hosts:

Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠